Clinical trials: in Netherlands
Non-small Cell Lung Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07195695
- Testing
- Zongertinib, Pembrolizumab, Atezolizumab
- Where
- 203 sites in United States, Argentina and 26 more
- Volunteers
- 400 people
- Sponsor
- Boehringer Ingelheim
Focal Epilepsy, Tonic-Clonic Seizures
An Open-label Study of XEN1101 in Epilepsy
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of…
- Trial name
- X-TOLE4 (NCT05718817)
- Testing
- XEN1101
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 880 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Trial name
- NCT05607550
- Testing
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 398 people
- Sponsor
- ArriVent BioPharma, Inc.
Ulcerative Colitis (UC)
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
- Trial name
- LEGACY (NCT01848561)
- Where
- 512 sites in United States, Australia and 19 more
- Volunteers
- 8,250 people
- Sponsor
- AbbVie
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 191 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Aortic Valve Stenosis
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe…
- Trial name
- NCT02701283
- Testing
- Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR)
- Where
- 87 sites in United States, Australia and 5 more
- Volunteers
- 2,223 people
- Sponsor
- Medtronic Cardiovascular
Fabry Disease
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study evaluating kidney Gb3 inclusions (and other histologic lesions) in male…
- Trial name
- NCT03737214
- Testing
- Lucerastat
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 107 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Genmab
Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the…
- Trial name
- EasyBoost (NCT07357675)
- Testing
- EA-230 90mg/kg/hour
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 300 people
- Sponsor
- EBI Anti Sepsis BV
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease…
- Trial name
- PHOENYCS FLY (NCT06617325)
- Testing
- DZP
- Where
- 245 sites in United States, Argentina and 21 more
- Volunteers
- 450 people
- Sponsor
- UCB Biopharma SRL
Crohn's Disease
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately…
- Trial name
- NCT06233461
- Testing
- TAK-279
- Where
- 201 sites in United States, Australia and 23 more
- Volunteers
- 268 people
- Sponsor
- Takeda
Urothelial Cancer
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy…
- Trial name
- CheckMate901 (NCT03036098)
- Testing
- Nivolumab, Ipilimumab, Gemcitabine
- Where
- 174 sites in United States, Argentina and 28 more
- Volunteers
- 1,314 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
- Trial name
- STEP HFpEF DM (NCT04916470)
- Testing
- Semaglutide
- Where
- 180 sites in United States, Argentina and 14 more
- Volunteers
- 617 people
- Sponsor
- Novo Nordisk A/S
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and…
- Trial name
- NCT04619004
- Testing
- Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
- Where
- 123 sites in United States, Australia and 14 more
- Volunteers
- 277 people
- Sponsor
- Daiichi Sankyo
Major Depressive Disorder
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Trial name
- NCT06966401
- Testing
- NBI-1065845
- Where
- 120 sites in United States, Australia and 21 more
- Volunteers
- 850 people
- Sponsor
- Neurocrine Biosciences
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- NCT05716100
- Testing
- XEN1101
- Where
- 103 sites in United States, Argentina and 19 more
- Volunteers
- 360 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Cancer-associated Cachexia
Visugromab in Cachexia International Trial
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia.
- Trial name
- VINCIT (NCT07112196)
- Testing
- Visugromab (CTL-002)
- Where
- 79 sites in United States, Bulgaria and 12 more
- Volunteers
- 518 people
- Sponsor
- CatalYm GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.